Date: 2014-10-02
Type of information: Collaboration agreement
Compound: NuQ®assays
Company: VolitionRx (Singapore) MD Anderson Cancer Center’s Department of Genitourinary Medical Oncology (USA - TX)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease: prostate cancer
Details: * On October 2, 2014, VolitionRx, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, announced a study collaboration with The University of Texas MD Anderson Cancer Center’s Department of Genitourinary Medical Oncology. The study will examine the competency of VolitionRx NuQ®assays to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration-resistant prostate cancer (CRPC), a less aggressive form. The retrospective study will include samples obtained from two previous clinical trials, one that selected men with CRPC who met one of seven anaplastic clinical criteria, and a second that included unselected men with non-anaplastic CRPC. The samples will be assessed using VolitionRx’s assays for specific histone modifications of circulating nucleosomes. Patterns and changes in histone modifications are used to indicate certain cancers and this method will assess the competency of VolitionRx’s assays to identify anaplastic CRPC. Archived serum samples obtained from patients participating in two prospective clinical trials will be used for these studies: 1.Phase II Study of Carboplatin plus Docetaxel in Patients with Anaplastic Prostate Carcinoma (Aparicio et al. Clin Cancer Res. 2013 Jul 1;19(13):3621-30). 2.A Prospective Randomized Phase III Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer (Non-anaplastic-NCT00024167). To be eligible for this study, men with typical metastatic CRPC had to have osteoblastic bone metastases and were excluded if they had predominant visceral metastases to liver, lungs or brain, symptomatic lymphadenopathy, significant local invasive disease or SCPC. In addition to this planned study, VolitionRx is carrying out several clinical trials on the effectiveness of the NuQ® assays as a cancer diagnostic tool: A 4,800 patient retrospective study and a 14,000 patient prospective study into colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark.
A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany.
A 250 patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium.
Financial terms:
Latest news:
